Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

In this online program, experts discuss best practices and emerging strategies in CAR T-cell therapy for patients with leukemia, lymphoma, and myeloma. Watch the on-demand Webcast, download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries to learn more about how to integrate CAR T-cells into your clinical practice.
Matthew J. Frigault, MD
James K. Kochenderfer, MD
Jae H. Park, MD
person default
Stephen J. Schuster, MD

Downloadable Slidesets

Download this slideset for expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with ALL.

Jae H. Park, MD Released: December 6, 2019

Download this slideset for expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.

person default Stephen J. Schuster, MD Released: December 6, 2019

Download this slideset for expert perspectives on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma.

James K. Kochenderfer, MD Released: December 6, 2019

Download this slideset for expert perspectives on managing toxicities associated with CAR T-cell therapy.

Matthew J. Frigault, MD Released: December 6, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation
Kite, A Gilead Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue